Literature DB >> 19595531

Combination of stromal-derived factor-1alpha and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularization.

Jian-Xing Yu1, Xue-Fei Huang, Wei-Ming Lv, Cai-Sheng Ye, Xin-Zhi Peng, Hui Zhang, Long-Bin Xiao, Shen-Ming Wang.   

Abstract

BACKGROUND: Recruitment and entrapment of bone marrow-derived endothelial progenitor cells (EPCs) is important in vascular endothelial growth factor (VEGF)-induced angiogenesis. EPC mobilization and differentiation are modulated by stromal-derived factor-1alpha (SDF-1alpha/CXCL12), another important chemokine. In this study, we investigated the hypothesis that SDF-1alpha and VEGF might act synergistically on EPC-mediated vasculogenesis.
METHODS: EPCs were isolated and cultured from human peripheral blood, then transduced with retroviral vectors pBabe containing human VEGF(165) complimentary DNA (Td/V-EPCs) and pBabe wild-type (Td/p-EPCs). EPC migration activity was investigated with a modified Boyden chamber assay. EPC apoptosis induced by serum starvation was studied by annexin V assays. The combined effect of local administration of SDF-1alpha and Td/V-EPC transplantation on neovascularization was investigated in a murine model of hind limb ischemia.
RESULTS: Over-expression of hVEGF(165) increased SDF-1alpha-mediated EPC migration. SDF-1alpha-mediated migration was significantly increased when EPCs were modified with VEGF (Td/V-EPCs) vs when VEGF was not present (Td/p-EPCs) or when VEGF alone was present (Td/V-EPCs; 196.8 +/- 15.2, 81.2 +/- 9.8, and 67.4 +/- 7.4/mm(2), respectively P < .001). SDF-1alpha combined with VEGF reduced serum starvation-induced apoptosis of EPCs more than SDF-1alpha or VEGF alone (P < .001). To determine the effect of this combination in vivo, SDF-1alpha was locally injected alone into the ischemic hind limb muscle of nude mice or combined with systemically injected Td/V-EPCs. The SDF-1alpha plus VEGF group showed significantly increased local accumulation of EPCs, blood-flow recovery, and capillary density compared with the other groups. The ratio of ischemic/normal blood flow in Td/V-EPCs plus SDF-1alpha group was significantly higher (P < .01), as was capillary density (capillaries/mm(2)), an index of neovascularization (Td/V-EPCs plus SDF-1alpha group, 863 +/- 31; no treatment, 395 +/-13; SDF-1alpha, 520 +/- 29; Td/p-EPCs, 448 +/- 28; Td/p-EPCs plus SDF-1alpha, 620 +/- 29; Td/V-EPCs, 570 +/- 30; P < .01). To investigate a possible mechanistic basis, we showed that VEGF up-regulated the receptor for SDF-1alpha, CXCR4, on EPCs in vitro.
CONCLUSION: The combination of SDF-1alpha and VEGF greatly increases EPC-mediated angiogenesis. The use VEGF and SDF-1alpha together, rather than alone, will be a novel and efficient angiogenesis strategy to provide therapeutic neovascularization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19595531     DOI: 10.1016/j.jvs.2009.05.049

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  27 in total

1.  Juxtacrine and paracrine interactions of rat marrow-derived mesenchymal stem cells, muscle-derived satellite cells, and neonatal cardiomyocytes with endothelial cells in angiogenesis dynamics.

Authors:  Reza Rahbarghazi; Seyed Mahdi Nassiri; Parvaneh Khazraiinia; Abdol-Mohammad Kajbafzadeh; Seyed Hossein Ahmadi; Elham Mohammadi; Mohammad Molazem; Mohamad Zamani-Ahmadmahmudi
Journal:  Stem Cells Dev       Date:  2012-12-12       Impact factor: 3.272

Review 2.  Stem cell recruitment after injury: lessons for regenerative medicine.

Authors:  Robert C Rennert; Michael Sorkin; Ravi K Garg; Geoffrey C Gurtner
Journal:  Regen Med       Date:  2012-11       Impact factor: 3.806

Review 3.  New strategies for improving stem cell therapy in ischemic heart disease.

Authors:  Peisen Huang; Xiaqiu Tian; Qing Li; Yuejin Yang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  Endothelial progenitor cells: therapeutic perspective for ischemic stroke.

Authors:  Yu-Hui Zhao; Bin Yuan; Ji Chen; De-Hui Feng; Bin Zhao; Chao Qin; Yan-Fang Chen
Journal:  CNS Neurosci Ther       Date:  2012-12-11       Impact factor: 5.243

Review 5.  Cell therapy of peripheral arterial disease: from experimental findings to clinical trials.

Authors:  Zankhana Raval; Douglas W Losordo
Journal:  Circ Res       Date:  2013-04-26       Impact factor: 17.367

6.  Therapeutic angiogenesis using genetically engineered human endothelial cells.

Authors:  Seung-Woo Cho; Fan Yang; Sun Mi Son; Hyun-Ji Park; Jordan J Green; Said Bogatyrev; Ying Mei; Sohyun Park; Robert Langer; Daniel G Anderson
Journal:  J Control Release       Date:  2012-03-15       Impact factor: 9.776

7.  Molecular imaging of bone marrow mononuclear cell survival and homing in murine peripheral artery disease.

Authors:  Koen E A van der Bogt; Alwine A Hellingman; Maarten A Lijkwan; Ernst-Jan Bos; Margreet R de Vries; Juliaan R M van Rappard; Michael P Fischbein; Paul H Quax; Robert C Robbins; Jaap F Hamming; Joseph C Wu
Journal:  JACC Cardiovasc Imaging       Date:  2012-01

8.  A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction.

Authors:  Dan-yan Xu; Benjamin B Davis; Zhen-he Wang; Shui-ping Zhao; Binaya Wasti; Zhe-liang Liu; Ning Li; Christophe Morisseau; Nipavan Chiamvimonvat; Bruce D Hammock
Journal:  Int J Cardiol       Date:  2012-04-21       Impact factor: 4.164

Review 9.  Concise Review: Endothelial Progenitor Cells in Regenerative Medicine: Applications and Challenges.

Authors:  Mark Seow Khoon Chong; Wei Kai Ng; Jerry Kok Yen Chan
Journal:  Stem Cells Transl Med       Date:  2016-03-08       Impact factor: 6.940

10.  Stromal cell-derived factor-1-directed bone marrow mesenchymal stem cell migration in response to inflammatory and/or hypoxic stimuli.

Authors:  Yang Yu; Rui-Xin Wu; Li-Na Gao; Yu Xia; Hao-Ning Tang; Fa-Ming Chen
Journal:  Cell Adh Migr       Date:  2016-01-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.